Therapeutic approaches to brain tumors remain a challenge, with considerable limitations
regarding delivery of drugs. There has been renewed and increasing interest in translating …

Theranostic pairs have proven value in thyroid diseases, neuroendocrine tumours (NET),
and prostate cancer [1, 2]. Recently, the Food and Drug Administration and the European …

Brain tumors are notoriously difficult to treat. The blood-brain barrier provides a sanctuary
site where residual and metastatic cancer cells can evade most therapeutic modalities. The …

The development of clinical trials has led to substantial improvements in the prevention and
treatment of many diseases, including brain cancer. Advances in medicine, such as …

Personalized medicine is presented as the future of patient care. Nuclear Medicine will play
a major role in the selection of patients for targeted therapies and in early therapy …

Both primary and metastatic brain tumors carry poor prognoses despite modern advances in
medical therapy, radiation therapy, and surgical techniques. Gliomas, including …

The advent of theranostics (formed by merging the words therapeutics and diagnostics) is a
significant event in the era of precision medicine because it allows us to understand the …

Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful
mainly due to the beneficial effects of image-guided therapeutic concepts for patients …

The optimum selection of the appropriate radiolabelled probe for the right target and the
right patient is the foundation of theranostics in personalised medicine. In nuclear medicine …

Cytotoxic chemotherapy, a mainstay of non-surgical cancer therapy for many decades and
often combined with external beam radiotherapy, can be viewed as a “carpet bombing” …